Full Press Release Details
Affimed Announces Annual General Meeting of Shareholders
Heidelberg, Germany, May 22, 2023 Affimed N.V. (Nasdaq: AFMD) ( Affimed , or the Company ), a clinical-stage
immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its 2023 Annual General Meeting of Shareholders (the Annual Meeting ) will be held on June 21, 2023 at 2:00 p.m. CET
at the NH Collection Amsterdam Barbizon Palace, Prins Hendrikkade 59-72, 1012 AD Amsterdam, the Netherlands.
notice and agenda of the Annual Meeting are available on Affimed s website at https://www.affimed.com/investors/corporate-governance/ under Annual General Meeting , as well as the SEC s website at www.sec.gov.
Affimed (Nasdaq: AFMD) is a
clinical-stage immuno-oncology company committed to give patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The Company s proprietary ROCK platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination
The ROCK platform predictably generates customized innate cell engager (ICE ) molecules, which use patients immune cells to destroy tumor cells. This innovative approach enabled Affimed to become the first company with a clinical-stage ICE . Headquartered in Heidelberg, Germany, with offices in New York, NY, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by a bold vision to stop cancer from
ever derailing patients lives. For more about the Company s people, pipeline and partners, please visit: www.affimed.com.
Affimed Investor Contact:
Director, Investor Relations
E-Mail: a.fudukidis@affimed.com
Tel.: +1 (917) 436-8102